Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma

19Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

It is reported that surveillance of serum p53 antibody (Ab) is a useful marker in detecting esophageal squamous cell carcinoma (ESCC). But there is little reported about prognostic significance of serum p53-Ab in postoperative patients with ESCC. The aim of this study is to evaluate the significance of preoperative serum p53-Ab as a marker of early recurrence after curative resection for ESCC. Enzyme-linked immunosorvent assay (ELISA) was used to analyze serum p53-Ab before treatment in 44 patients with ESCC. Carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) were examined by immunoradiometric assay. The patients who were strongly positive and positive in serum p53-Ab were more likely to have early recurrence after curative resection than seronegative patients. There were no significant correlations between CEA, SCC-Ag positivity and early recurrence. We found that serum p53-Ab was useful to predict a risk of early recurrence after curative surgical resection for ESCC. © 2007 The Authors. Journal compilation © 2007 The International Society for Diseases of the Esophagus.

Cite

CITATION STYLE

APA

Takahashi, K., Miyashita, M., Nomura, T., Makino, H., Futami, R., Kashiwabara, M., … Tajiri, T. (2007). Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Diseases of the Esophagus, 20(2), 117–122. https://doi.org/10.1111/j.1442-2050.2007.00656.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free